'Special K' could relieve depression

June 7, 2012
Professor Colleen Loo

(Medical Xpress) -- Recreational drug and anaesthetic, ketamine, is being trialled in people with severe depression and is providing almost instant relief from symptoms, offering fresh hope of a quick new way to manage the illness at its worst.

Ketamine, known colloquially as “Special K”, has been shown to alleviate in a matter of minutes or hours instead of the weeks it can take some conventional medications to treat the illness.

University of New South Wales researchers are leading the Australia-first clinical trial of to determine if it could be the next frontier in treating depression, which affects around 15 per cent of the population.

Professor Colleen Loo, from UNSW’s School of Psychiatry and the Black Dog Institute, says while traditional antidepressant drugs remain useful, ketamine is envisaged as an additional treatment option, not a replacement.

“The magnitude of improvement we’re seeing within 24 hours is just astounding compared to existing antidepressant treatments,” Professor Loo says.

“The only other antidepressant treatment that comes anything close to it is electro-convulsive therapy, or ECT, the most effective proven treatment for depression.”

Researchers are investigating the body’s response to ketamine by administering a range of small doses in the placebo-controlled trial, given by intravenous infusion under careful medical monitoring.

Ketamine works on a different part of the brain from other traditional antidepressants, which is helping researchers understand more about the brain and its role in depression.

“It’s a paradigm shift. All the other existing antidepressant medications work on receptor systems like serotonin, noradrenaline and dopamine, whereas this works on the glutamate system,” Professor Loo says.

A successful, ongoing trial could mean ketamine will be used in Australia in clinical settings within a decade.

More information: Ketamine has so far been successfully trialled on a handful of people, with more participants being recruited. Anyone interested in participating in the trial should email n.katalinic@unsw.edu.au , contact 02 9113 1637 or visit the Black Dog Institute website for more information.
Candidates for the treatment are those adults with severe depression in need of medication but who haven’t responded to traditional treatments.

Related Stories

Ketamine improved bipolar depression within minutes

May 30, 2012

Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide ...

Recommended for you

Neural efficiency hypothesis confirmed

July 27, 2015

One of the big questions intelligence researchers grapple with is just how differences in intelligence are reflected in the human brain. Researchers at ETH Zurich have succeeded in studying further details relating to suspected ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Eventide
1 / 5 (1) Jun 08, 2012
Ecstasy deserves a shot at depression treatments trials too.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.